Skip to content

Multi-parametric Magnetic Resonance Imaging for the Precise Diagnosis and Quantitative Study of Liver Steatosis, Inflammation, and Fibrosis in Chronic Liver Disease.

Multi-parametric Magnetic Resonance Imaging for the Precise Diagnosis and Quantitative Study of Liver Steatosis, Inflammation, and Fibrosis in Chronic Liver Disease.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06463366
Enrollment
100
Registered
2024-06-17
Start date
2022-06-14
Completion date
2025-09-01
Last updated
2025-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Stiffness

Brief summary

To construct a novel, non-invasive, accurate, and convenient method to achieve the degree of liver damage is an important general problem in the management of patients with chronic liver disease. The investigators would like to develop non invasive advanced Magnetic Resonance Imaging (MRI) techniques (MR elastography, MRI-PDFF) to assess the degree of liver damage in patients with chronic liver disease. These techniques could reach high diagnostic performance for detection of liver fibrosis, inflammation and liver fat content; and could decrease the number of liver biopsies, which have risks and sample only a small portion of the liver.

Detailed description

Patients with chronic hepatitis have increased risks of liver damage, including fibrosis and cirrhosis, which may eventually lead to hepatocellular carcinoma and end-stage liver disease requiring liver transplantation. These diseases are/will be the source of enormous health care costs and morbidity/mortality in the China. Most hepatologists still rely on liver biopsy findings in patients newly diagnosed with chronic hepatitis, which enables the assessment of liver damage (fibrosis and inflammation). Liver biopsy has limitations, including cost, invasiveness, poor patient acceptance, limited sampling, inter-observer variability and is difficult to repeat. Non invasive tests to capture the extent of liver damage at a larger scale are urgently needed. These will gain more acceptance among patients and hepatologists. In this proposal, the investigators would like to test and validate non invasive MRI methods based on advanced MR elastography and MRI-PDFF techniques for the detection of fibrosis, cirrhosis and liver fat content in patients with chronic hepatitis. In order to improve the diagnostic performance of MRI, the investigators would like to build and validate a predictive model based on advanced functional MRI metrics (storage modulus, loss modulus and damping ratio \[DR\]) by follow up every 6 month. If validated, this novel non invasive algorithm will not only decreases the number of liver biopsies, but also enable earlier diagnosis of liver fibrosis when antiviral treatment is more effective, and enable a comprehensive evaluation of the liver (to assess for cirrhosis, portal hypertension and hepatocellular cancer). This study is aimed to evaluate whether the change of liver stiffness assessed by MRE can predict treatment effectiveness in chronic liver disease treatment by follow up every 6 month.

Interventions

DEVICE3D-MRE,MRI-PDFF

3D-MRE(storage modulus, ., loss modulus and damping ratio \[DR\] for liver inflammation and fibrosis) MRI-PDFF(liver fat content)

Sponsors

Shengjing Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Chronic liver disease (including viral hepatitis, alcoholic hepatitis, non alcoholic steatohepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, etc..) 2. Age range of 18 to 75 years old 3. Accept systematic antiviral therapy or hormone or ursodesoxycholic acid or supportive liver protection therapy

Exclusion criteria

1. Age less than 18 years 2. Unable or unwilling to give informed consent 3. Contra-indications to MRI 4. Electrical implants such as cardiac pacemakers or perfusion pumps 5. Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants 6. Ferromagnetic objects such as jewelry or metal clips in clothing 7. Pregnant subjects 8. Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions

Design outcomes

Primary

MeasureTime frameDescription
the changes of liver stiffness assessed by 3D-MRE before and after treatment.12 monthsLiver stiffness regression is defined as the change of 3D MRE shear stiffness larger than 19%

Countries

China

Contacts

Primary ContactYu Shi
18940259980@163.com+86 189 4025 9980
Backup ContactRuobing Bai
18940258589@163.com+86 189 4025 8589

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026